Ro
PrivateLast Round
Series D
Extension
Feb 15, 2022
Est. Valuation
$7B
Total Funding Raised
$1.03B
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Ro is a telehealth company offering a direct-to-consumer platform that facilitates diagnosis and convenient medication delivery, specializing in services for erectile dysfunction and smoking cessation with personalized treatment options.
Sector
Healthcare & Life Sciences
Verticals
Telemedicine, Pharma Supply Chain, D2C Brands, Subscription Commerce, Patient Engagement
Business Model
B2C
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ro Comparables
Compare Ro with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hims & Hers Health, Inc. | 92% | |
| Hexens | 88% | |
| LifeMD Inc | 87% |
Ro Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D Extension | Feb 15, 2022 | ||||
| Series D | Mar 23, 2021 | ||||
| Series C | Jul 27, 2020 | ||||
| Series B | Apr 16, 2019 | ||||
| Series A | Sep 18, 2018 | ||||
Seed | Nov 6, 2017 |
Key People
Founding team and executive leadership
Ro Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Torch Capital | Series D, Series A, Series C |
| Slow Ventures | Seed, Series A, Series B |
| 776 Capital | Series D |
| FirstMark Capital | Series D Extension, Series C, Series D, Series A, Series B |
| The Radcliff Companies | Series D |
| Dragoneer Investment Group | Series D |
| The Chernin Group | Series D Extension, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 2, 2026
Partnered with Eli Lilly to launch Zepbound KwikPen nationwide.
- Apr 2, 2026
Launched the FDA-approved Zepbound KwikPen nationwide.
Ro Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessAppears On
Curated lists and screens where this company is featured.
Frequently Asked Questions
Common questions about Ro's valuation, stock price, and market status.
Is Ro a public or private company?
Ro is a private company.
What is the current stock price of Ro?
Ro is a private company with no public stock price. No recent secondary market data is available.
How much is Ro worth (valuation)?
Ro's valuation is estimated at $7.0B based on funding round data.
Can I buy Ro stock?
Ro shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Ro's last funding round?
Ro's most recent funding round was Series D Extension on February 15, 2022.
Who are the main investors in Ro?
Key investors in Ro include FirstMark Capital, ShawSpring Partners, General Catalyst, TQ Ventures, TQ Ventures.
Will Ro IPO soon?
No public IPO plans have been announced for Ro.
How can I track Ro secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ro's secondary market activity and sign up for updates.